Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa study of PBF-677 in mild to moderate ulcerative colitis
2017-003228-54Phase 2Active
- Sponsor
- Palobiofarma
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing PBF-677 with Placebo (2 arms). Primary endpoint: Safety and tolerability of PBF-677. Started Apr 2018; status: active.
02
Drugs
PBF-677
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2017-003228-54.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003228-54.